Kondo, Douglas G.
Forrest, Lauren N.
Shi, Xianfeng
Sung, Young-Hoon
Hellem, Tracy L.
Huber, Rebekah S.
Renshaw, Perry F.
Funding for this research was provided by:
National Institute of Mental Health (5R21MH096858)
Article History
Received: 27 November 2015
Accepted: 3 February 2016
First Online: 23 February 2016
Compliance with ethical standards
:
: Dr. Renshaw and Dr. Kondo are co-inventors on United States and international patent applications that describe the use of creatine analogs to treat depressive disorders. The applications have been assigned to the University of Utah, which manages faculty conflicts of interest through its Office of Research Integrity and Compliance. Ms. Forrest, Dr. Shi, Dr. Sung, Dr. Hellem and Dr. Huber have no conflict of interest to declare.
: The University of Utah Institutional Review Board (IRB) approved this study. All procedures performed for this study were done in compliance with IRB regulations and in accordance with the ethical principles of the World Medical Association (WMA) 1964 Declaration of Helsinki and the subsequent revisions adopted by the WMA General Assembly in 1975, 1983, 1989, 1996, 2000, 2002, 2004, 2008 and 2013. This article does not contain or report any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in this study. For minor participants, informed assent was obtained from the participant, as well as written parental permission from the participant’s parent or legal guardian.